Laboratory cross-comparison of homologous recombination repair mutation analysis in tumor in a multicenter epithelial ovarian cancer series: The BORNEO GEICO 60-0 study.
Ignacio Romero(Valencian Infertility Institute), Ana Vivancos(Vall d'Hebron Institute of Oncology), Alfonso Yubero(Marqués de Valdecilla University Hospital), Alejandro Gallego(Hospital Universitario La Paz), Lorena Fariñas Madrid(Vall d'Hebron Hospital Universitari), Pilar Barretina Ginesta(Hospital Universitario Son Espases), Ana B. Sánchez(Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana), Ana Oaknin(Hebron University), Juan Cueva(Instituto de Investigación Sanitaria de Santiago), José Antonio López‐Guerrero(Consejo Superior de Investigaciones Científicas), Andrés Poveda(Hospital Quirónsalud Barcelona), Isabel Palacio Vázquez(Hospital Universitario Central de Asturias), Cristina Segura, Zaida García‐Casado(Fundación Instituto Valenciano de Oncología), Raúl Márquez(MD Anderson Cancer Center Madrid), Judit Matito(Oryzon Genomics (Spain))
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k